• Kramer, Van Dyck

  • Sep 27 2024
  • Length: 12 mins
  • Podcast

Kramer, Van Dyck

Listen for free

View show details

  • Summary

  • Lynn D. Kramer, MD, FAAN, Chief Clinical Officer, Deep Human Biology Learning at Eisai and a member of the Eisai Executive Committee, and Christopher van Dyck, MD, Professor of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, provide an overview of key results from the Clarity AD clinical trial assessing the safety and efficacy of lecanemab in people with early Alzheimer disease presented at the 2024 Alzheimer's Association International Conference. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Show More Show Less
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Kramer, Van Dyck

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available